Optimizing the Alcyone Trial: Efficacy of Daratumumab And Bortezomib Maintenance in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Post Dara-Vmp Induction, 1 Year Analysis

被引：0

作者：

Tamariz-Amador, Luis Esteban ^{[1
]}

Puertas, Borja ^{[2
]}

Hernandez, Miguel ^{[3
]}

Garcia, Alfonso ^{[4
]}

Jesus Blanchard, Maria ^{[5
]}

Ramirez-Payer, Angel ^{[6
]}

Lerma, Ana ^{[7
]}

Escalante, Fernando ^{[8
]}

Cobo-Rodriguez, Maria Teresa ^{[9
]}

Barez-Garcia, Abelardo ^{[10
]}

Gonzalez-Perez, Marta ^{[11
]}

De Soto, Teresa ^{[12
]}

Suarez-Cabrera, Alexia ^{[13
]}

Martinez-Castro, Margarita ^{[14
]}

Sancho Val, Luis Ignacio ^{[15
]}

Dios Loureiro, Ana ^{[16
]}

Yus Cebrian, Flor ^{[17
]}

Anguita, Magdalena ^{[18
]}

Alonso, Arancha ^{[19
]}

Gimenez Mesa, Eugenio ^{[20
]}

Angel Mendez, Jose ^{[21
]}

Jose Lahuerta, Juan ^{[22
]}

Blade, Joan ^{[23
]}

San-Miguel, Jesus ^{[24
]}

Mateos Manteca, Maria-Victoria ^{[25
]}

机构：

[1] Clin Univ Navarra, IDISNA, Dept Hematol, Pamplona, Spain

[2] Univ Hosp Salamanca, Hematol, Salamanca, Spain

[3] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[4] Hosp Clin Univ Valladolid, Valladolid, Spain

[5] Hosp Univ Ramon & Cajal, Madrid, Spain

[6] Hosp Univ Cent Asturias, Oviedo, Spain

[7] Hosp Univ Gen Nuestra Senora Prado, Talavera De La Reina, Spain

[8] Hosp Univ Leon, Leon, Spain

[9] Hosp Univ Sureste, Madrid, Spain

[10] Complejo Asistencial Avila, Avila, Portugal

[11] Hosp Clin Univ Santiago, Santiago, Chile

[12] Hosp Univ La Paz, La Paz, Mexico

[13] Hosp Univ Gran Canaria Doctor Negrin, Las Palmas Gran Canaria, Spain

[14] Complejo Hosp Univ Vigo, Vigo, Spain

[15] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

[16] Complejo Hosp Univ Pontevedra, Pontevedra, Spain

[17] Hosp Univ San Jorge, Zaragoza, Spain

[18] Complejo Hosp Jaen, Jaen, Spain

[19] Hosp Univ Ruber Juan Bravo, Madrid, Spain

[20] Hosp Univ Infanta Sofia, Sofia, Bulgaria

[21] Complejo Hosp Univ Orense, Orense, Spain

[22] Hosp Univ 12 Octubre, Madrid, Spain

[23] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[24] Clin Univ Navarra, Navarra, Spain

[25] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, CIBERONC, Salamanca, Spain

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-369

引用

页码：S246 / S247

页数：2

共 50 条

[1] Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Bobin, Arthur
Kyheng, Maeva
Guidez, Stephanie
Gruchet-Merouze, Cecile
Richez, Valentine
Duhamel, Alain
Karlin, Lionel
Kolb, Brigitte
Tiab, Mourad
Araujo, Carla
Meuleman, Nathalie
Malfuson, Jean-Valere
Bourquard, Pascal
Lenain, Pascal
Perrot, Aurore
Roussel, Murielle
Jaccard, Arnaud
Petillon, Marie-Odile
Belhadj-Merzoug, Karim
Chretien, Marie-Lorraine
Fontan, Jean
Rodon, Philippe
Schmitt, Anna
Offner, Fritz
Voillat, Laurent
Cereja, Sophie
Kuhnowski, Frederique
Rigaudeau, Sophie
Decaux, Olivier
Humbrecht-Kraut, Catherine
Frayfer, Jamile
Fitoussi, Olivier
Roos-Weil, Damien
Eisenmann, Jean Claude
Dorvaux, Veronique
Voog, Eric G.
Moreau, Philippe
Avet-Loiseau, Herve
Hulin, Cyrille
Facon, Thierry
Leleu, Xavier
LEUKEMIA, 2022, 36 (03) : 881 - 884
[2] Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Arthur Bobin
Maéva Kyheng
Stéphanie Guidez
Cécile Gruchet-Merouze
Valentine Richez
Alain Duhamel
Lionel Karlin
Brigitte Kolb
Mourad Tiab
Carla Araujo
Nathalie Meuleman
Jean-Valère Malfuson
Pascal Bourquard
Pascal Lenain
Aurore Perrot
Murielle Roussel
Arnaud Jaccard
Marie-Odile Petillon
Karim Belhadj-Merzoug
Marie-Lorraine Chretien
Jean Fontan
Philippe Rodon
Anna Schmitt
Fritz Offner
Laurent Voillat
Sophie Cereja
Frédérique Kuhnowski
Sophie Rigaudeau
Olivier Decaux
Catherine Humbrecht-Kraut
Jamile Frayfer
Olivier Fitoussi
Damien Roos-Weil
Jean Claude Eisenmann
Véronique Dorvaux
Eric G. Voog
Philippe Moreau
Hervé Avet-Loiseau
Cyrille Hulin
Thierry Facon
Xavier Leleu
Leukemia, 2022, 36 : 881 - 884
[3] Newly diagnosed Multiple Myeloma Daratumumab-Rd - a Standard for non-transplant Eligible Patients
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) : 380 - 381
[4] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136 (08) : 936 - 945
[5] ASH 2021 New clinical Data and Analysis on Daratumumab-Rd in newly diagnosed, non-transplant eligible Patients with multiple Myeloma
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
[6] IFM guidelines on induction and maintenance for patients with newly diagnosed transplant eligible multiple myeloma
Macro, Margaret
HEMATOLOGIE, 2019, 25 (01): : 30 - 40
[7] Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial
Fujisaki, Tomoaki
Ishikawa, Takayuki
Takamatsu, Hiroyuki
Suzuki, Kenshi
Min, Chang-Ki
Lee, Jae Hoon
Wang, Jianping
Carson, Robin
Crist, Wendy
Qi, Ming
Nagafuji, Koji
ANNALS OF HEMATOLOGY, 2019, 98 (12) : 2805 - 2814
[8] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2020, 136
[9] Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial
Tomoaki Fujisaki
Takayuki Ishikawa
Hiroyuki Takamatsu
Kenshi Suzuki
Chang-Ki Min
Jae Hoon Lee
Jianping Wang
Robin Carson
Wendy Crist
Ming Qi
Koji Nagafuji
Annals of Hematology, 2019, 98 : 2805 - 2814
[10] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2021, 138

← 1 2 3 4 5 →